Accropeutics, a Suzhou, China-based clinical-stage biotechnology firm that develops novel therapeutics that focus on molecular mechanisms of regulated cell dying for immune mediated illnesses, raised $12M in Collection B funding.
The spherical was led by Shenzhen Capital Group (SCGC), an current investor, with participation from Morningside Ventures, additionally an current investor, and new traders Chief Enterprise Funding (SZTI) and Hefei Sci-Tec Enterprise Capital (HFST).
The corporate intends to make use of the funds to develop operations and its enterprise attain.
Led by CEO Dr. Xiaohu (Jason) Zhang, Accropeutics is a clinical-stage biotechnology firm pioneering the invention, improvement and commercialization of novel therapeutics for immune mediated inflammatory illness, by focusing on molecular mechanisms of regulated cell dying. The corporate has a portfolio of compounds in varied phases of improvement, starting from lead optimization to medical testing. AC-101, a selective RIPK2 inhibitor, has accomplished Part I medical trials in Australia and China, and is at present present process a Part Ib trial for Ulcerative Colitis (UC). AC-201, a selective TYK2/JAK1 inhibitor, has accomplished Part I research in Australia and China, and is at present present process a Part II trial for Psoriasis in China. AC-003, a selective RIPK1 inhibitor, has accomplished Part I medical trials in China and the US as of August 2023, and is at present present process a Part Ib medical trial in aGVHD.
Accropeutics’ pipeline additionally consists of belongings within the analysis and pre-clinical phases of improvement. Accropeutics owns international rights for all of its belongings, and boasts 23 issued patents in China, Japan, Korea, US and the EU.
FinSMEs
14/03/2025
